I agree that this site is using cookies. You can find further informations here.
X
Advani, R.
831  results:
Search for persons X
?
1

Long term outcome of Peripheral T Cell Lymphomas: 10y follo..:

Civallero, M. ; Advani, R. ; Horwitz, S....
Hematological Oncology.  41 (2023)  S2 - p. 491-492 , 2023
Link: https://doi.org/10.1002/..
 
?
2

OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, A..:

Messmer, M. ; Stack, A. ; Deng, M....
Hematological Oncology.  41 (2023)  S2 - p. 156-158 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Baseline PET Total Metabolic Tumor Volume has a prognostic ..:

Skrypets, T. ; Chauvie, S. ; Manni, M....
Hematological Oncology.  41 (2023)  S2 - p. 349-349 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Mature T and NK cell lymphomas classified according to 2016..:

Manni, M. ; Chiattone, C. S. ; Prince, M. H....
Hematological Oncology.  41 (2023)  S2 - p. 311-312 , 2023
Link: https://doi.org/10.1002/..
 
?
5

DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIV..:

Alig, S. K. ; Esfahani, M. Shahrokh ; Garofalo, A....
Hematological Oncology.  41 (2023)  S2 - p. 96-98 , 2023
Link: https://doi.org/10.1002/..
 
?
6

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere.  6 (2022)  - p. 102-103 , 2022
Link: https://doi.org/10.1097/..
 
?
7

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB..:

Hutchings, M. ; Ansell, S. M. ; Straus, D. J....
HemaSphere.  6 (2022)  - p. 101-102 , 2022
Link: https://doi.org/10.1097/..
 
?
8

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
?
9

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐C..:

Witzig, T. ; Sokol, L. ; Kim, W....
Hematological Oncology.  37 (2019)  S2 - p. 64-65 , 2019
Link: https://doi.org/10.1002/..
 
?
10

IBRUTINIB MONOTHERAPY PRODUCES LONG‐TERM DISEASE CONTROL IN..:

Treon, S.P. ; Meid, K. ; Gustine, J....
Hematological Oncology.  37 (2019)  S2 - p. 184-185 , 2019
Link: https://doi.org/10.1002/..
 
?
11

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISP..:

Topp, M.S. ; Arnason, J. ; Advani, R....
Hematological Oncology.  37 (2019)  S2 - p. 90-92 , 2019
Link: https://doi.org/10.1002/..
 
?
12

BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY..:

Dickinson, M. ; Briones Mejjide, J. ; Herrera, A.F....
Hematological Oncology.  37 (2019)  S2 - p. 174-175 , 2019
Link: https://doi.org/10.1002/..
 
?
13

RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS..:

Jagadeesh, D. ; Horwitz, S. ; Bartlett, N.L....
Hematological Oncology.  37 (2019)  S2 - p. 470-471 , 2019
Link: https://doi.org/10.1002/..
 
?
14

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLU..:

Diefenbach, C.S. ; Hong, F. ; Ambinder, R....
Hematological Oncology.  37 (2019)  S2 - p. 123-124 , 2019
Link: https://doi.org/10.1002/..
 
?
15

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB ..:

Advani, R. ; Bartlett, N.L. ; Smith, S.M....
Hematological Oncology.  37 (2019)  S2 - p. 89-90 , 2019
Link: https://doi.org/10.1002/..
 
1-15